PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.

Abstract This meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME).
PMID
Related Publications

Intravitreal bevacizumab and dexamethasone implant for treatment of chronic diabetic macular edema.

A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.

Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study.

A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.

Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.

Authors

Mayor MeshTerms

Drug Implants

Keywords

Anti-VEGF

Dexamethasone implant

Diabetic macular edema

Meta-analysis

Ozurdex

Journal Title bmc ophthalmology
Publication Year Start




PMID- 29784048
OWN - NLM
STAT- MEDLINE
DCOM- 20180525
LR  - 20180525
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 18
IP  - 1
DP  - 2018 May 21
TI  - A meta-analysis of the effect of a dexamethasone intravitreal implant versus
      intravitreal anti-vascular endothelial growth factor treatment for diabetic
      macular edema.
PG  - 121
LID - 10.1186/s12886-018-0779-1 [doi]
AB  - BACKGROUND: This meta-analysis evaluated the effectiveness and safety of
      dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth
      factor (VEGF) treatment for diabetic macular edema (DME). METHODS: The PubMed,
      Embase, clinicaltrials.gov website and Cochrane Library databases were
      comprehensively searched for studies comparing DEX implant with anti-VEGF in
      patients with DME. Best-corrected visual acuity (BCVA), central subfield
      thickness (CST) and adverse events were extracted from the final eligible
      studies. Review Manager (RevMan) 5.3 for Mac was used to analyze the data and
      GRADE profiler were used to access the quality of outcomes. RESULTS: Based on
      four randomized clinical trials assessing a total of 521 eyes, the DEX implant
      can achieve visual acuity improvement for DME at rates similar to those achieved 
      via anti-VEGF treatment (mean difference [MD] = - 0.43, P = 0.35), with superior 
      anatomic outcomes at 6 months (MD = - 86.71 mum, P = 0.02), while requiring fewer
      injections, in comparison to anti-VEGF treatment. Although the mean reduction in 
      CST did not showed significant difference at 12 months (MD = - 33.77 mum, P =
      0.21), the significant in BCVA from baseline to 12 months supported the anti-VEGF
      treatment (MD = - 3.26, P < 0.00001). No statistically significant differences in
      terms of the serious adverse events. However, use of the DEX implant has higher
      risk of intraocular pressure elevation and cataract than anti-VEGF treatment.
      CONCLUSIONS: Compared with anti-VEGF, DEX implant improved anatomical outcomes
      significantly. However, this did not translate to improved visual acuity, which
      may be due to the progression of cataract. Therefore, the DEX implant may be
      recommended as a first chioce for select cases, such as for pseudophakic eyes,
      anti-VEGF-resistant eyes, or patients reluctant to receive intravitreal
      injections frequently.
FAU - He, Ye
AU  - He Y
AD  - Department of Retina, Tianjin Medical University Eye Hospital, 251 Fukang Road,
      Tianjin, 300384, China.
FAU - Ren, Xin-Jun
AU  - Ren XJ
AD  - Department of Retina, Tianjin Medical University Eye Hospital, 251 Fukang Road,
      Tianjin, 300384, China.
FAU - Hu, Bo-Jie
AU  - Hu BJ
AD  - Department of Retina, Tianjin Medical University Eye Hospital, 251 Fukang Road,
      Tianjin, 300384, China.
FAU - Lam, Wai-Ching
AU  - Lam WC
AD  - Department of Ophthalmology, The University of Hong Kong, Hong Kong, China.
FAU - Li, Xiao-Rong
AU  - Li XR
AD  - Department of Retina, Tianjin Medical University Eye Hospital, 251 Fukang Road,
      Tianjin, 300384, China. [email protected]
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20180521
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Drug Implants)
RN  - 0 (Glucocorticoids)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/*administration & dosage/adverse effects
MH  - Anti-Inflammatory Agents/*administration & dosage/adverse effects
MH  - Bevacizumab
MH  - Delayed-Action Preparations
MH  - Dexamethasone/*administration & dosage/adverse effects
MH  - Diabetic Retinopathy/*drug therapy
MH  - *Drug Implants
MH  - Glucocorticoids/*administration & dosage/adverse effects
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy
MH  - Ranibizumab
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - Visual Acuity
OTO - NOTNLM
OT  - Anti-VEGF
OT  - Dexamethasone implant
OT  - Diabetic macular edema
OT  - Meta-analysis
OT  - Ozurdex
EDAT- 2018/05/23 06:00
MHDA- 2018/05/26 06:00
CRDT- 2018/05/23 06:00
PHST- 2017/11/26 00:00 [received]
PHST- 2018/04/27 00:00 [accepted]
PHST- 2018/05/23 06:00 [entrez]
PHST- 2018/05/23 06:00 [pubmed]
PHST- 2018/05/26 06:00 [medline]
AID - 10.1186/s12886-018-0779-1 [doi]
AID - 10.1186/s12886-018-0779-1 [pii]
PST - epublish
SO  - BMC Ophthalmol. 2018 May 21;18(1):121. doi: 10.1186/s12886-018-0779-1.